Skip to content
Insider tapeLive · 5:07 PM ET
My stocks

Thomas Haughey

At a glance: Thomas Haughey is Director at Ani Pharmaceuticals (ANIP). Their latest SEC Form 4, filed Jun 10, 2026, reported a sale of $162K. On file: 0 purchase lines ($0) and 1 sale line ($162K).

Disclosed holdings: about $2.7M of ANIP stock: 38,878 shares reported on their latest Form 4 (filed Jun 10, 2026), valued at the Nov 20, 2026 close of $69.11. This counts only ANIP shares reported to the SEC; it leaves out cash, other investments, options and unvested awards, so it is not total net worth.

Director at Ani Pharmaceuticals Inc (ANIP)

Purchase track record

Not enough history. Based on 0 purchases with a full 90 days of price history.

—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $162K

Thomas Haughey's InsiderPrint

3 trades from SEC Form 4 filings, 2020 to 2026, drawn as one fingerprint.

InsiderPrint of Thomas Haughey: 3 trades, 2020 to 20262020: 1 buy, 0 sales2021: 1 buy, 0 sales2022: 0 buys, 0 sales2023: 0 buys, 0 sales2024: 0 buys, 0 sales2025: 0 buys, 0 sales2026: 0 buys, 1 sale

Reading this print: Mostly buys, trading about once a year, typically $98K a trade; most sales are on a pre-planned 10b5-1 schedule.

  • Bump outward: a purchase (2)
  • Dent inward: a sale (1)
  • One ring per year, oldest in the middle, Jan at the top going clockwise. Bigger bumps mean more dollars.

Insiders with a similar print

  1. Stuart BoddenCEO · RNGR · 99% match
  2. Sean Davis KellDirector · PRCH · 99% match
  3. Daniel R. ChardCEO, Chair · MED · 99% matchTheir buys since 2022: 1 of 3 beat the S&P 500
  4. Mahtiyar BonakdarpourCTO, President · ROOT · 98% match
  5. Paul M. BarbasDirector · VST · 98% match

Matched on seven traits of each insider's trading pattern (buy share, pace, typical size, planned sales, seasonality, buying after drops, number of companies). Pattern matching on public filings; history, not a prediction.

Every purchase since 2020

From the SEC's insider data sets: each open-market buy by Thomas Haughey, matched to how the stock did over the next 90 days against the S&P 500.

0 of 2 buys beat the S&P 500 (0%), median -19.7% vs. the index. Small sample: treat with care. All insider buys: 46%.

StockFiled90 days vs. S&P 500
ANIPDec 9, 2021-5.0%
ANIPMar 5, 2020-34.4%

Buys made close together in one stock count once. Price-only returns; history, not a prediction.

Reported trades

Filed Stock Type Shares Price Value Since
Jun 10SEC ANIPAni Pharmaceuticals Inc Sell Plan 2,00038,878 held (−5%) $80.88 $162K -14.6%
  • Sell

    Director Thomas Haughey sold $162K of ANIP at $80.88 — pre-scheduled 10b5-1 plan sale.

Follow Thomas Haughey

Get one email when Thomas Haughey files a new purchase or sale. Free.

At most one email a day about Thomas Haughey, plus the free Monday email. Already subscribed? Use the same email to add them. Unsubscribe anytime. Facts from public filings, not advice.